MetaVia is trading 10.1% down at $1.24 on October 26, with no confirmed company-specific catalyst identified.
- The latest company news found was the October 13 appointment of Sarah Browne as chief medical officer.
- Major U.S. indexes were higher, so the decline did not align with a broad-market drop.
- No volume or trading-activity data was provided, leaving the immediate catalyst unclear.